Clinical trials: Stage III Lung Cancer
Carcinoma, Non-Small-Cell Lung
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
To compare the pairwise PK similarities between BAT3306, EU-Keytruda, and US-Keytruda, all administered with pemetrexed and carboplatin.
- Trial name
- NCT06280196
- Testing
- BAT3306, EU-Keytruda®, US-Keytruda®
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Bio-Thera Solutions
NSCLC (Advanced Non-small Cell Lung Cancer)
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
This study aims to evaluate the safety and efficacy of SCTB41 combined with docetaxel in patients with previously treated non-small cell lung cancer. The Phase II part of this study is an open-label, multicenter clinical trial.
- Trial name
- NCT07609251
- Testing
- SCTB41, docetaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sinocelltech Ltd.
Carcinoma, Non-Small Cell Lung
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
- Trial name
- ARTEMIDELung04 (NCT06868277)
- Testing
- Rilvegostomig, Pembrolizumab
- Where
- 304 sites in United States, Argentina and 25 more
- Volunteers
- 830 people
- Sponsor
- AstraZeneca
Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV
A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is a phase Ib/II , open-label, multicenter single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 combined with Carboplatin and Pemetrexed/ Paclitaxel as…
- Trial name
- NCT04647344
- Testing
- AK104 plus Carboplatin and Pemetrexed, AK104 plus Carboplatin and paclitaxel
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Akeso
Extensive-stage Small Cell Lung Cancer
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
Phase II Study is to Evaluate the Safety and tolerability of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.
- Trial name
- NCT04254471
- Testing
- AL3810, carboplatin + etoposide
- Where
- China
- Volunteers
- 313 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
The goal of this clinical trial is to compare the amount of study drug in patients' blood to confirm that SB27 works in the same way as EU and US sourced Keytruda in early or locally advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT06268613
- Testing
- SB27, EU sourced Keytruda, US sourced Keytruda
- Where
- 24 sites in Poland, South Korea and 2 more
- Volunteers
- 163 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Non - Small Cell Lung Cancer NSCLC
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of…
- Trial name
- ARCTIC (NCT02352948)
- Testing
- MEDI4736 (durvalumab), Vinorelbine, Gemcitabine
- Where
- 201 sites in United States, Australia and 24 more
- Volunteers
- 597 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
The primary objective of the study is to compare overall survival of participants randomized to receiving custirsen in combination with docetaxel with participants randomized to receive docetaxel alone.
- Trial name
- ENSPIRIT (NCT01630733)
- Testing
- Custirsen, Docetaxel
- Where
- 78 sites in United States, Australia and 12 more
- Volunteers
- 664 people
- Sponsor
- Achieve Life Sciences
Non-small Cell Lung Cancer (NSCLC)
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer…
- Trial name
- SKYSCRAPER-03 (NCT04513925)
- Testing
- Atezolizumab, Tiragolumab, Durvalumab
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 829 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
This prospective, double-blind, randomized study will evaluate the safety and efficacy of two dose levels of erlotinib [Tarceva] on progression-free survival, response and disease control rates and overall survival in patients…
- Trial name
- NCT01183858
- Testing
- Erlotinib [Tarceva]
- Where
- 63 sites in China, Denmark and 7 more
- Volunteers
- 315 people
- Sponsor
- Hoffmann-La Roche
KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
The study is being conducted to evaluate the efficacy, and safety of HRS-7058 in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
- Trial name
- NCT07601048
- Testing
- HRS-7058, Fulzerasib Tablets, Garsorasib Tablets
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
Non-Small Cell Lung Cancer
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
A Phase 1/2 multi-center open-label study of BGB324 (bemcentinib) as a single agent (Run-in Cohort) and in combination with erlotinib (Arms A, B, and C) in participants with Stage IIIb or Stage IV non-small cell lung cancer…
- Trial name
- NCT02424617
- Testing
- Erlotinib, Bemcentinib
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- BerGenBio ASA
Non Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.
This is an observational study, aiming to investigate whether the ctDNA dynamics analyzed by the K-TrackTM assay could predict early response to Tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung…
- Conditions
- Non Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT06167460
- Where
- Vietnam
- Volunteers
- 50 people
- Sponsor
- Gene Solutions
Advanced Non-small Cell Lung Cancer
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
The main object of this trial is to offer treatment of recombinant endostatin ( Sulijia) combined with Vinorelbine and Cisplatin (NP) plus maintenance therapy with Sulijia for advanced Non-small Cell Lung Cancer, expecting to…
- Trial name
- NCT03117335
- Testing
- Sulijia
- Where
- 37 sites in China
- Volunteers
- 560 people
- Sponsor
- Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Lung Cancer, Non-squamous, Non-small Cell
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including…
- Trial name
- NCT06151574
- Testing
- zongertinib, pembrolizumab, cisplatin
- Where
- 163 sites in United States, Argentina and 24 more
- Volunteers
- 428 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this clinical trial is to compare Utidelone with Docetaxel in patients with locally advanced or metastatic non-small cell lung cancer previously failed platinum-containing chemotherapy regimens.
- Trial name
- NCT05673590
- Testing
- Utidelone Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Small-cell Lung Cancer
The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.
The study is being conducted to evaluate the efficacy and safety of SHR-1316 in combination with chemo-radiotherapy in patients with LS-SCLC.
- Trial name
- NCT04691063
- Testing
- SHR-1316; Carboplatin; Etoposide；Radiotherapy, Palcebo; Carboplatin; Etoposide；Radiotherapy
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.